We are live on ! Find out more
NVS icon

Novartis

848 hedge funds and large institutions have $22B invested in Novartis in 2014 Q2 according to their latest regulatory filings, with 69 funds opening new positions, 291 increasing their positions, 342 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

62% more call options, than puts

Call options by funds: $170M | Put options by funds: $105M

44% more first-time investments, than exits

New positions opened: 69 | Existing positions closed: 48

7% more capital invested

Capital invested by funds: $20.6B → $22B (+$1.42B)

2% more funds holding

Funds holding: 831848 (+17)

0.04% less ownership

Funds ownership: 9.82%9.79% (-0.04%)

3% less funds holding in top 10

Funds holding in top 10: 6058 (-2)

15% less repeat investments, than reductions

Existing positions increased: 291 | Existing positions reduced: 342

Holders
848
Holders Change
+17
Holders Change %
+2.05%
% of All Funds
24.36%
Holding in Top 10
58
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-3.33%
% of All Funds
1.67%
New
69
Increased
291
Reduced
342
Closed
48
Calls
$170M
Puts
$105M
Net Calls
+$65.2M
Net Calls Change
+$75.2M
Name Holding Trade Value Shares
Change
Change in
Stake
Dodge & Cox
1
Dodge & Cox
California
$4.63B +$409M +5,201,731 +10%
Primecap Management
2
Primecap Management
California
$2.16B -$14.8M -187,879 -0.7%
BBHC
3
Brown Brothers Harriman & Co
New York
$1.03B -$87.1M -1,107,204 -8%
Wells Fargo
4
Wells Fargo
California
$639M +$10.4M +132,836 +2%
BTS
5
BB&T Securities
Virginia
$619M -$929K -11,816 -2%
Fisher Asset Management
6
Fisher Asset Management
Washington
$540M +$7.08M +90,035 +1%
U
7
UBS
Switzerland
$397M +$18.1M +229,901 +5%
Northern Trust
8
Northern Trust
Illinois
$365M +$70.3M +893,343 +25%
MAA
9
Managed Account Advisors
New Jersey
$359M +$20M +254,277 +6%
Loomis, Sayles & Company
10
Loomis, Sayles & Company
Massachusetts
$277M +$16.4M +207,950 +6%
Fidelity Investments
11
Fidelity Investments
Massachusetts
$255M -$13.4M -169,843 -5%
ClearBridge Investments
12
ClearBridge Investments
New York
$254M -$27.5M -349,379 -10%
Invesco
13
Invesco
Georgia
$254M -$101M -1,288,640 -29%
Parnassus Investments
14
Parnassus Investments
California
$246M +$37.9M +481,473 +19%
Franklin Resources
15
Franklin Resources
California
$239M -$122M -1,555,335 -35%
Capital Research Global Investors
16
Capital Research Global Investors
California
$228M +$5.09M +64,728 +2%
Boston Partners
17
Boston Partners
Massachusetts
$219M -$10.3M -130,591 -5%
Manulife (Manufacturers Life Insurance)
18
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$216M +$12.3M +156,458 +6%
Neuberger Berman Group
19
Neuberger Berman Group
New York
$215M -$14M -177,901 -6%
WI
20
WHV Investments
California
$213M -$6.99M -88,929 -3%
EARNEST Partners
21
EARNEST Partners
Georgia
$212M -$3.01M -38,317 -1%
Bank of America
22
Bank of America
North Carolina
$208M -$25.4M -323,204 -11%
Macquarie Group
23
Macquarie Group
Australia
$198M +$12.6M +159,709 +7%
Lazard Asset Management
24
Lazard Asset Management
New York
$191M +$7.27M +92,375 +4%
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
$186M -$1.62M -20,646 -0.9%

NVS Hedge Fund Activity: Q2 2014 in Review

848 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q2 2014, worth a combined $22B — up 6.9% from $20.6B a quarter earlier.

Buyers outnumbered sellers: 69 funds opened new NVS positions and 48 closed out — a net gain of 21 holders — while 291 added to existing stakes and 342 trimmed.

The largest buyer was Dodge & Cox, adding an estimated $409M. The largest seller was Hotchkis & Wiley Capital Management, cutting an estimated $145M.

  • 848 institutional investors held Novartis (NVS) as of Q2 2014, up from 831 in Q1 2014.
  • Funds reported $22B of Novartis stock for Q2 2014, up 6.9% quarter-over-quarter.
  • 69 funds opened new Novartis positions in Q2 2014 and 48 closed out, a net change of +21 holders.
  • The largest Novartis buyer in Q2 2014 was Dodge & Cox, an estimated $409M added.
  • The largest Novartis seller in Q2 2014 was Hotchkis & Wiley Capital Management, an estimated $145M sold.

Based on aggregated 13F filings for Q2 2014.